The clinical relevance of decreased miR-150 expression has also been highlighted by studies describing its role as a tumor suppressor in lymphoma and most recently examining how decreased expression promotes leukemogenesis in MLL-AF9 and MLL-ENL rearranged leukemia [27,31]. This evidence concerns the gene KMT2A and lymphoma.